结核病筛查提高预防性治疗接受率(TB SCRIPT)试验:乌干达HIV感染者个体随机对照试验研究方案
TB SCRIPT是一项3期、多中心、单盲、个体1:1随机对照试验,旨在比较基于C反应蛋白(CRP)的结核病筛查策略与基于症状的筛查策略对HIV感染者临床结局的效果。主要复合终点为2年结核病发病率和全因死亡率,中间结局包括 prevalent 结核病例检出和结核病预防性治疗(TPT)接受率。研究结果将为改善TPT合格HIV感染者的筛选及WHO指南提供随机证据。
要点
- WHO推荐对HIV感染者进行系统性结核病筛查,筛查阳性者需确诊检测,筛查阴性且符合条件者应接受TPT。
- 症状筛查在高负担地区仍是标准做法,但特异性差,导致许多无活动性结核的高风险HIV感染者未转介TPT。
- CRP筛查具有与症状筛查相当的敏感性和更高特异性,2021年获WHO认可,但其对结核病负担的影响尚不明确。
核心结论
- 该研究将评估基于CRP的结核病筛查对HIV感染者2年结核病发病率和全因死亡率复合终点、现患结核病例检出及TPT接受率的效果。
- 研究结果旨在改善TPT合格HIV感染者的筛选,并为扩大和整合结核病筛查与TPT活动提供随机证据以指导WHO指南。
研究设计与样本
- TB SCRIPT为3期、多中心、单盲、个体1:1随机对照试验,比较基于CRP的结核病筛查策略与基于症状的筛查策略(当前实践)。
- CRP筛查采用即时检验(POC)检测CRP水平。
- 试验注册于ClinicalTrials.gov(NCT04557176),注册日期为2020年9月21日。
主要发现
- 主要复合终点为2年结核病发病率和全因死亡率。
- 中间结局包括现患结核病例检出和TPT接受率。
- 原文未报告本试验的研究结果。
关键数值与推荐
- WHO推荐对HIV感染者进行系统性结核病筛查,筛查阳性者进行确诊结核检测,筛查阴性且符合TPT条件的HIV感染者接受TPT。
- CRP筛查策略在2021年获WHO认可,其敏感性可与症状筛查相比,特异性高于症状筛查。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People living with HIV (PLHIV) have an increased risk of developing active tuberculosis (TB). To reduce the burden of TB among PLHIV, the World Health Organization (WHO) recommends systematic TB screening followed by (1) confirmatory TB testing for all who screen positive and (2) TB preventive therapy (TPT) for all TPT-eligible PLHIV who screen negative. Symptom-based screening remains the standard of care in most high TB burden settings, including Uganda. Despite having high sensitivity for active TB among antiretroviral-naïve PLHIV, symptom screening has poor specificity; as such, many high-risk PLHIV without active TB are not referred for TPT. C-reactive protein (CRP) is a promising alternative strategy for TB screening that has comparable sensitivity and higher specificity than symptom screening, and was endorsed by WHO in 2021. However, the impact of CRP-based TB screening on TB burden for PLHIV remains unclear. METHODS: TB SCRIPT (TB Screening Improves Preventive Therapy Uptake) is a phase 3, multi-center, single-blinded, individual (1:1) randomized controlled trial evaluating the effectiveness of CRP-based TB screening on clinical outcomes of PLHIV. The trial aims to compare the effectiveness of a TB screening strategy based on CRP levels using a point-of-care (POC) assay on 2-year TB incidence and all-cause mortality (composite primary trial endpoint) and prevalent TB case detection and uptake of TPT (intermediate outcomes), relative to symptom-based TB screening (current practice). DISCUSSION: This study will be critical to improving selection of eligible PLHIV for TPT and helping guide the scale-up and integration of TB screening and TPT activities. This work will enable the field to improve TB screening by removing barriers to TPT initiation among eligible PLHIV, and provide randomized evidence to inform and strengthen WHO guidelines. TRIAL REGISTRATION: ClinicalTrials.gov NCT04557176. Registered on September 21, 2020.
引用
- Semitala FC, Chaisson LH, Dowdy DW, et al. Tuberculosis screening improves preventive therapy uptake (TB SCRIPT) trial among people living with HIV in Uganda: a study protocol of an individual randomized controlled trial. Trials. 2022. PMID: 35550621. doi:10.1186/s13063-022-06371-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。